142 related articles for article (PubMed ID: 21517772)
1. Cyclin dependent kinase 1 inhibitors: a review of recent progress.
Wang Q; Su L; Liu N; Zhang L; Xu W; Fang H
Curr Med Chem; 2011; 18(13):2025-43. PubMed ID: 21517772
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
3. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
5. Identification and structural-functional analysis of cyclin-dependent kinases of the cattle tick Rhipicephalus (Boophilus) microplus.
Gomes H; Romeiro NC; Braz GR; de Oliveira EA; Rodrigues C; da Fonseca RN; Githaka N; Isezaki M; Konnai S; Ohashi K; da Silva Vaz I; Logullo C; Moraes J
PLoS One; 2013; 8(10):e76128. PubMed ID: 24146826
[TBL] [Abstract][Full Text] [Related]
6. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
[TBL] [Abstract][Full Text] [Related]
7. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
8. Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1.
Zhang L; Zhu H; Wang Q; Fang H; Xu W; Li M
J Mol Model; 2011 Feb; 17(2):219-26. PubMed ID: 20419498
[TBL] [Abstract][Full Text] [Related]
9. Animal Models for Studying the In Vivo Functions of Cell Cycle CDKs.
Risal S; Adhikari D; Liu K
Methods Mol Biol; 2016; 1336():155-66. PubMed ID: 26231715
[TBL] [Abstract][Full Text] [Related]
10. CDK1 in Breast Cancer: Implications for Theranostic Potential.
Izadi S; Nikkhoo A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Yousefi M; Jadidi-Niaragh F
Anticancer Agents Med Chem; 2020; 20(7):758-767. PubMed ID: 32013835
[TBL] [Abstract][Full Text] [Related]
11. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome.
Lindqvist A; Källström H; Lundgren A; Barsoum E; Rosenthal CK
J Cell Biol; 2005 Oct; 171(1):35-45. PubMed ID: 16216921
[TBL] [Abstract][Full Text] [Related]
12. PP2A inhibitors arrest G2/M transition through JNK/Sp1- dependent down-regulation of CDK1 and autophagy-dependent up-regulation of p21.
Gong FR; Wu MY; Shen M; Zhi Q; Xu ZK; Wang R; Wang WJ; Zong Y; Li ZL; Wu Y; Zhou BP; Chen K; Tao M; Li W
Oncotarget; 2015 Jul; 6(21):18469-83. PubMed ID: 26053095
[TBL] [Abstract][Full Text] [Related]
13. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
15. Measurement of Cdk1/Cyclin B Kinase Activity by Specific Antibodies and Western Blotting.
Lewis CW; Taylor RG; Golsteyn RM
Methods Mol Biol; 2016; 1342():337-48. PubMed ID: 26254935
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
18. Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: design, synthesis, and biological evaluation.
Liu T; Xu Z; He Q; Chen Y; Yang B; Hu Y
Bioorg Med Chem Lett; 2007 Jan; 17(1):278-81. PubMed ID: 17085048
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026.
Seong YS; Min C; Li L; Yang JY; Kim SY; Cao X; Kim K; Yuspa SH; Chung HH; Lee KS
Cancer Res; 2003 Nov; 63(21):7384-91. PubMed ID: 14612537
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
Le Brazidec JY; Pasis A; Tam B; Boykin C; Black C; Wang D; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
Bioorg Med Chem Lett; 2012 Mar; 22(5):2070-4. PubMed ID: 22326168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
